Article Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as ﬁrst-line treatmentfor non-squamous non-small cell lung cancer Graphical abstract Highlights dNEO-PV-01 plus chemotherapy and anti-PD-1 is feasible and safe in ﬁrst-line NSCLC dRegimen generates durable and cytotoxic neoantigen-speciﬁc T cell responses dNeoantigen-speciﬁc CD4+T cells have an activated effector phenotype dVaccine-induced T cells induce epitope spread to mutantKRAS epitopesAuthors Mark M. Awad, Ramaswamy Govindan,Kristen N.